People · Operator
Named in public records as an officer, director or promoter · active 2019–2023 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nitrome Biosciences, Inc | — | Biotechnology | Series B | $18.9M | $680.1M | 2020 |
| ImmunoMolecular Therapeutics, Inc. | — | Biotechnology | Series A | $10.8M | $215.8M | 2019 |
| Violet Therapeutics, Inc. | — | Pharma | Series A | $7.4M | $65.7M | 2023 |
| Endlyz Therapeutics, Inc. | — | Biotechnology | Seed | $3.3M | $81.2M | 2021 |
Jonathan Behr at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jonathan Behr on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jason Dinges | 1 | 8 |
| Meredith Fisher | 1 | 6 |
| Margarita Chavez | 1 | 4 |
| Sean Doherty | 1 | 4 |
| JOHN GUSTOFSON | 1 | 3 |
| Atsushi Usami | 1 | 3 |
| Steve Orndorff | 1 | 3 |
| Ephraim Heller | 1 | 2 |
| William E Yelle | 1 | 2 |
| Henrijette Richter | 1 | 2 |
| Tom Shea | 1 | 2 |
| Regis Kelly | 1 | 1 |
| Regis W. Kelly | 1 | 1 |
| Zach W. Hall | 1 | 1 |
| William W. McDowell | 1 | 1 |
| Ephreim Heller | 1 | 1 |
| Aaron Michels | 1 | 1 |
| Ed Orr | 1 | 1 |
| Peter Gottlieb | 1 | 1 |
| Joanna Wolak | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.